Welcome to our dedicated page for Tango Therapeutics SEC filings (Ticker: TNGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tango Therapeutics, Inc. filings document a clinical-stage precision oncology business and its Nasdaq-listed common stock. Current reports disclose operating and financial results, business highlights for vopimetostat and related development programs, material agreements, capital-raising arrangements such as at-the-market common stock sales, and updates to governance and executive leadership.
Proxy and compensation disclosures cover board matters, executive pay, pay-versus-performance data, equity awards, and shareholder voting matters. The company’s filings also address officer appointments and departures, separation and employment agreements, compensatory arrangements, capital structure, risk factors, and other material events affecting its biotechnology operations.
TNGX submitted a Form 144 notice for proposed sales of Common Stock effective 06/11/2026. The filing lists a $51,523,582.08 figure and multiple lots: 1,791,726 shares (entry), 1,625,739 shares tied to a stock option exercise with a 06/11/2026 date, and 165,987 shares described as restricted stock from 04/01/2017. The excerpt also discloses a reported sale by Daniella Beckman of 4,446 shares on 06/10/2026 for $133,380.00.
The filing names Morgan Stanley Smith Barney LLC as broker and indicates NASDAQ as the market. This Form 144 notifies the SEC and provides holder/sale details; it does not itself execute transfers.
Tango Therapeutics, Inc. entered into an underwriting agreement for an underwritten public offering of 18,166,667 shares of common stock and pre-funded warrants to purchase up to 1,833,395 additional shares. The shares are priced at $30.00 each and the pre-funded warrants at $29.999 each, reflecting a $0.001 exercise price.
The company also granted underwriters a 30-day option to buy up to 3,000,009 additional shares. Tango estimates net proceeds of approximately $566.5 million, to be used for general corporate purposes, including research and development, pivotal trial expenses, commercialization preparation, and capital expenditures. Based on its current plan, it believes existing funds plus this offering will support operations into 2030.
Tango Therapeutics is offering 18,166,667 shares of common stock and pre-funded warrants to purchase 1,833,395 shares. The public offering price is $30.00 per share (pre-funded warrant price $29.999) and the offering is being made pursuant to a shelf registration statement. The underwriters may purchase up to an additional 3,000,009 shares. Net proceeds to the company are estimated at approximately $566.5 million, which the company intends to use for general corporate purposes, R&D, pivotal trial expenses and potential commercialization preparation.
Issuer submitted a Form 144 notice reporting proposed sales of common stock. The filing lists a stock option exercise tied to 914 shares dated 06/10/2026 and restricted stock of 3,532 shares dated 03/16/2017. The broker listed is Morgan Stanley Smith Barney LLC and an amount of $133,380.00 appears in the record.
Tango Therapeutics director John B. Ketchum received an equity grant consisting of 4,000 restricted stock units and an option for 25,000 shares of Common Stock. The RSUs vest in full on the earlier of June 5, 2027 or the next annual stockholder meeting, subject to continued service. The stock option, with a $20.22 exercise price, vests in 12 equal monthly installments beginning July 5, 2026 and expires on June 5, 2036. Following these grants, Ketchum directly holds 24,937 shares of Common Stock.
Tango Therapeutics director Lesley Ann Calhoun received new equity awards, increasing her direct stake in the company. She was granted 4,000 shares of Common Stock in the form of restricted stock units and now directly holds 16,500 Common shares after this award.
She was also granted options to purchase 25,000 shares of Common Stock at an exercise price of $20.2200 per share, expiring on June 5, 2036. The RSUs vest in full on the earlier of June 5, 2027 or the next annual stockholder meeting, while the options vest in 12 equal monthly installments starting July 5, 2026, in each case subject to her continuous service.
Tango Therapeutics director Mace Rothenberg reported equity awards in the form of restricted stock units and stock options. The filing shows a grant of 4,000 shares of Common Stock represented by restricted stock units, plus a stock option for 25,000 shares at an exercise price of $20.2200 per share.
The restricted stock units vest in full on the earlier of June 5, 2027 or the next annual meeting of stockholders, subject to continuous service. The option vests in 12 substantially equal monthly installments over one year starting on July 5, 2026 and expires on June 5, 2036. After the stock grant, Rothenberg holds 41,500 shares of Common Stock directly.
Tango Therapeutics director Lee Sung received new equity awards consisting of restricted stock units and stock options. The filing shows a grant of 570 RSUs, each representing one share of common stock, increasing her direct common stock holdings to 22,870 shares after the award.
An additional stock option covering 3,570 shares of common stock was granted with an exercise price of $20.22 per share and an expiration date of June 5, 2036. The RSUs vest in full on the earlier of June 5, 2027 or the next annual stockholder meeting, while the option vests in 12 equal monthly installments starting July 5, 2026, in each case contingent on continued service.
Tango Therapeutics is offering $500,000,000 of its common stock pursuant to a preliminary prospectus supplement dated June 8, 2026. The offering is made under the company’s shelf registration on Form S-3. The prospectus states 144,162,543 shares outstanding as of March 31, 2026, and that net tangible book value was $391.5M, or $2.72 per share as of that date. The underwriters have a 30-day option to purchase up to an additional $75,000,000 of shares. The prospectus describes intended uses of proceeds for general corporate purposes, R&D, pivotal trial expenses and potential commercialization, and states the company expects proceeds plus existing cash to fund operations into 2030. The offering includes customary underwriting arrangements, a 60-day lock-up for certain insiders, and continued availability of an ATM program with up to $35.6M capacity as of June 5, 2026.
Tango Therapeutics reported initial Phase 1/2 data for its PRMT5 inhibitor vopimetostat combined with Revolution Medicines’ RAS(ON) inhibitors in hard‑to‑treat cancers. In previously treated MTAP‑deleted, RAS‑mutant pancreatic cancer, vopimetostat plus daraxonrasib produced a 92% objective response rate in 12 evaluable patients and a 90% six‑month progression‑free survival rate, with all patients achieving disease control.
Three non‑small cell lung cancer patients on the same combination all responded. A separate vopimetostat plus zoldonrasib arm in pancreatic cancer showed a 52% objective response rate and 74% six‑month progression‑free survival in 27 evaluable patients, with 96% disease control. Safety across combinations was generally favorable, with mostly mild or moderate side effects and no treatment‑related grade 4 or 5 events or discontinuations.
Based on these results, Tango plans to advance the vopimetostat plus daraxonrasib regimen into Phase 3 development as a front‑line, chemotherapy‑free option for MTAP‑deleted pancreatic cancer, while exploring second‑line registration paths and broader development of its PRMT5 franchise.